Infarct in a New Territory After Treatment Administration in the ESCAPE Randomized Controlled Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times).
BACKGROUND AND PURPOSE: Infarct in a new previously unaffected territory (INT) is a potential complication of endovascular treatment. We applied a recently proposed methodology to identify and classify INTs in the ESCAPE randomized controlled trial (Endovascular Treatment for Small Core and Anterior...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Heart Association
2016
|
_version_ | 1797055075611312128 |
---|---|
author | Ganesh, A Al-Ajlan, F Sabiq, F Assis, Z Rempel, J Butcher, K Thornton, J Kelly, P Roy, D Poppe, A Jovin, T Devlin, T Baxter, B Krings, T Casaubon, L Frei, D Choe, H Tampieri, D Teitelbaum, J Lum, C Mandzia, J Phillips, S Bang, O Almekhlafi, M Coutts, S Barber, P Sajobi, T Demchuk, A Eesa, M Hill, M Goyal, M Menon, B ESCAPE Trial Investigators |
author_facet | Ganesh, A Al-Ajlan, F Sabiq, F Assis, Z Rempel, J Butcher, K Thornton, J Kelly, P Roy, D Poppe, A Jovin, T Devlin, T Baxter, B Krings, T Casaubon, L Frei, D Choe, H Tampieri, D Teitelbaum, J Lum, C Mandzia, J Phillips, S Bang, O Almekhlafi, M Coutts, S Barber, P Sajobi, T Demchuk, A Eesa, M Hill, M Goyal, M Menon, B ESCAPE Trial Investigators |
author_sort | Ganesh, A |
collection | OXFORD |
description | BACKGROUND AND PURPOSE: Infarct in a new previously unaffected territory (INT) is a potential complication of endovascular treatment. We applied a recently proposed methodology to identify and classify INTs in the ESCAPE randomized controlled trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). <br/>METHODS: The core laboratory identified INTs on 24-hour follow-up imaging, blinded to treatment allocation, after assessing all baseline imaging. INTs were classified into 3 types (I-III) and 2 subtypes (A/B) based on size and if catheter manipulation was likely performed across the vessel territory ostium. Logistic regression was used to understand the effect of multiple a priori identified variables on INT occurrence. Ordinal logistic regression was used to analyze the effect of INTs on modified Rankin Scale shift at 90 days. <br/>RESULTS: From 308 patients included, 14 INTs (4.5% overall; 2.8% on follow-up noncontrast computed tomography, 11.7% on follow-up magnetic resonance imaging) were identified (5.0% in endovascular treatment arm versus 4.0% in control arm [P=0.7]). The use of intravenous alteplase was associated with a 68% reduction in the odds of INT occurrence (3.0% with versus 9.1% without; odds ratio, 0.32; 95% confidence interval, 0.11-0.96; adjusted for age, sex, and treatment type). No other variables were associated with INTs. INT occurrence was associated with reduced probability of good clinical outcome (common odds ratio, 0.25; 95% confidence interval, 0.09-0.74; adjusted for age, type of treatment, and follow-up scan). <br/>CONCLUSIONS: INTs are uncommon, detected more frequently on follow-up magnetic resonance imaging, and affect clinical outcome. In experienced centers, endovascular treatment is likely not causal, whereas intravenous alteplase may be therapeutic. <br/>CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01778335. |
first_indexed | 2024-03-06T19:06:17Z |
format | Journal article |
id | oxford-uuid:154127a4-1571-4db6-a334-52e6892c13b0 |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-06T19:06:17Z |
publishDate | 2016 |
publisher | American Heart Association |
record_format | dspace |
spelling | oxford-uuid:154127a4-1571-4db6-a334-52e6892c13b02022-03-26T10:24:29ZInfarct in a New Territory After Treatment Administration in the ESCAPE Randomized Controlled Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times).Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:154127a4-1571-4db6-a334-52e6892c13b0EnglishSymplectic Elements at OxfordAmerican Heart Association2016Ganesh, AAl-Ajlan, FSabiq, FAssis, ZRempel, JButcher, KThornton, JKelly, PRoy, DPoppe, AJovin, TDevlin, TBaxter, BKrings, TCasaubon, LFrei, DChoe, HTampieri, DTeitelbaum, JLum, CMandzia, JPhillips, SBang, OAlmekhlafi, MCoutts, SBarber, PSajobi, TDemchuk, AEesa, MHill, MGoyal, MMenon, BESCAPE Trial InvestigatorsBACKGROUND AND PURPOSE: Infarct in a new previously unaffected territory (INT) is a potential complication of endovascular treatment. We applied a recently proposed methodology to identify and classify INTs in the ESCAPE randomized controlled trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). <br/>METHODS: The core laboratory identified INTs on 24-hour follow-up imaging, blinded to treatment allocation, after assessing all baseline imaging. INTs were classified into 3 types (I-III) and 2 subtypes (A/B) based on size and if catheter manipulation was likely performed across the vessel territory ostium. Logistic regression was used to understand the effect of multiple a priori identified variables on INT occurrence. Ordinal logistic regression was used to analyze the effect of INTs on modified Rankin Scale shift at 90 days. <br/>RESULTS: From 308 patients included, 14 INTs (4.5% overall; 2.8% on follow-up noncontrast computed tomography, 11.7% on follow-up magnetic resonance imaging) were identified (5.0% in endovascular treatment arm versus 4.0% in control arm [P=0.7]). The use of intravenous alteplase was associated with a 68% reduction in the odds of INT occurrence (3.0% with versus 9.1% without; odds ratio, 0.32; 95% confidence interval, 0.11-0.96; adjusted for age, sex, and treatment type). No other variables were associated with INTs. INT occurrence was associated with reduced probability of good clinical outcome (common odds ratio, 0.25; 95% confidence interval, 0.09-0.74; adjusted for age, type of treatment, and follow-up scan). <br/>CONCLUSIONS: INTs are uncommon, detected more frequently on follow-up magnetic resonance imaging, and affect clinical outcome. In experienced centers, endovascular treatment is likely not causal, whereas intravenous alteplase may be therapeutic. <br/>CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01778335. |
spellingShingle | Ganesh, A Al-Ajlan, F Sabiq, F Assis, Z Rempel, J Butcher, K Thornton, J Kelly, P Roy, D Poppe, A Jovin, T Devlin, T Baxter, B Krings, T Casaubon, L Frei, D Choe, H Tampieri, D Teitelbaum, J Lum, C Mandzia, J Phillips, S Bang, O Almekhlafi, M Coutts, S Barber, P Sajobi, T Demchuk, A Eesa, M Hill, M Goyal, M Menon, B ESCAPE Trial Investigators Infarct in a New Territory After Treatment Administration in the ESCAPE Randomized Controlled Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). |
title | Infarct in a New Territory After Treatment Administration in the ESCAPE Randomized Controlled Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). |
title_full | Infarct in a New Territory After Treatment Administration in the ESCAPE Randomized Controlled Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). |
title_fullStr | Infarct in a New Territory After Treatment Administration in the ESCAPE Randomized Controlled Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). |
title_full_unstemmed | Infarct in a New Territory After Treatment Administration in the ESCAPE Randomized Controlled Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). |
title_short | Infarct in a New Territory After Treatment Administration in the ESCAPE Randomized Controlled Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). |
title_sort | infarct in a new territory after treatment administration in the escape randomized controlled trial endovascular treatment for small core and anterior circulation proximal occlusion with emphasis on minimizing ct to recanalization times |
work_keys_str_mv | AT ganesha infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT alajlanf infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT sabiqf infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT assisz infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT rempelj infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT butcherk infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT thorntonj infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT kellyp infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT royd infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT poppea infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT jovint infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT devlint infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT baxterb infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT kringst infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT casaubonl infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT freid infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT choeh infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT tampierid infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT teitelbaumj infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT lumc infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT mandziaj infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT phillipss infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT bango infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT almekhlafim infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT couttss infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT barberp infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT sajobit infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT demchuka infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT eesam infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT hillm infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT goyalm infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT menonb infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes AT escapetrialinvestigators infarctinanewterritoryaftertreatmentadministrationintheescaperandomizedcontrolledtrialendovasculartreatmentforsmallcoreandanteriorcirculationproximalocclusionwithemphasisonminimizingcttorecanalizationtimes |